ABSI News and Press, Absci Corporation From 11/14/23

2023-11-14 17:26:35 ET More on Absci Absci, Almirall partner on dermatologic drug development Seeking Alpha’s Quant Rating on Absci Historical earnings data for Absci Financial information for Absci For further details see: Absci GAAP EPS o...

Entered into partnership with Almirall to rapidly develop novel treatments for dermatological diseases, for up to $664M in deal value, plus royalties Unveiled AI drug creation pipeline of four wholly-owned assets VANCOUVER, Wash. and NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Abs...

2023-11-14 07:33:17 ET Spanish drugmaker Almirall and biotech Absci ( NASDAQ: ABSI ) have forged a partnership to develop AI-designed therapeutics for chronic dermatological diseases. Leveraging its de novo generative AI technology, Absci ( ABSI ) will develop and commer...

VANCOUVER, Wash. and BARCELONA, Spain, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI ), a generative AI drug creation company, and Almirall S.A. ( BME: ALM ) , a global biopharmaceutical company focused on medical dermatology, today announced a drug discove...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Absci Corporation (ABSI) is expected to report $-0.23 for Q3 2023

VANCOUVER, Wash. and NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the speaker lineup for its inaugural R&D Day on Wednesday, October 4 th , 2023. The program will begin at 9:00 a.m. Eastern Time...

2023-09-20 07:47:47 ET More on Exscientia and AI drug discovery Seeking Alpha’s Quant Rating on Exscientia Exscientia Is Worth The AI-Driven Speculation Exscientia gains as enrollments begin for cancer trial AI to represent 11% of healthcare budgets in...

VANCOUVER, Wash. and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will host its first R&D Day on Wednesday, October 4 th , 2023 in New York City. The program will begin at 9:00 a.m. Easter...

2023-09-04 12:00:00 ET More on AI Cathie Wood's 'Big Ideas 2023' sees Artificial Intelligence as the future Artificial intelligence is a '1995 moment' for tech. That could push stocks even higher Apple CEO Tim Cook says artificial intelligence 'is a major focus of ou...